comparemela.com

Latest Breaking News On - News ratings for anebulo pharmaceuticals daily - Page 2 : comparemela.com

Short Interest in Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) Declines By 18 2%

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Free Report) was the recipient of a significant decline in short interest in January. As of January 31st, there was short interest totalling 2,700 shares, a decline of 18.2% from the January 15th total of 3,300 shares. Approximately 0.1% of the shares of the stock are short sold. Based […]

Anebulo Pharmaceuticals (ANEB) to Release Quarterly Earnings on Thursday

Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) is scheduled to be announcing its earnings results on Thursday, February 8th. Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. […]

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) Short Interest Down 14 0% in December

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) Short Interest Down 14 0% in December
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Anebulo Pharmaceuticals (ANEB) to Release Quarterly Earnings on Wednesday

Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) will announce its earnings results on Wednesday, November 8th. Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report) last announced its quarterly earnings results on Wednesday, September 20th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, analysts expect Anebulo […]

Benchmark Reiterates Speculative Buy Rating for Anebulo Pharmaceuticals (NASDAQ:ANEB)

Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Free Report)‘s stock had its “speculative buy” rating reissued by equities research analysts at Benchmark in a report issued on Tuesday, Benzinga reports. They currently have a $8.00 price objective on the stock. Benchmark’s target price suggests a potential upside of 151.97% from the stock’s previous close. ANEB has been […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.